Hypoprolactinemia attenuates rosuvastatin's cardiometabolic benefits in men, worsening lipid, inflammation, and glycemic markers.

Hypoprolactinemia is linked to elevated risk of vascular and metabolic diseases. While statins like rosuvastatin are standard for dyslipidemia and cardiovascular risk, evidence suggests that prolactin deficiency may attenuate their efficacy, particularly for lipid-lowering and insulin-sensitizing effects in women. This study addresses the gap by investigating if similar attenuation occurs in men, potentially impacting treatment strategies for cardiometabolic health.